{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-031103","form_type":"8-K","ticker":"ELTP","cik":"0001053369","company_name":"ELITE PHARMACEUTICALS INC /NV/","filed_at":"2026-06-29T20:51:57+00:00","discovered_at":"2026-06-29T20:53:12.181965+00:00","generated_at":"2026-06-29T20:53:21.081277+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Elite Pharma reports FY2026 revenue of $148.9M (+77% YoY), operating income $49.1M (+151%)","bullets":["Consolidated revenue $148.9M, up $64.8M (77%) vs prior year; operating profit $49.1M, up $29.5M (151%).","Growth driven by full-year contribution of Lisdexamfetamine, plus launches of Oxycodone Acetaminophen, Naltrexone, and Phentermine tablets.","Conference call on June 30, 2026 at 11:30 AM EDT; dial-in 1-800-346-7359 (domestic), conference number 98840.","Stockholders may submit financial questions by 7:00 PM EDT on June 29, 2026 via dianne@elitepharma.com."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-031103","json":"https://secwatch.observer/filing/0001493152-26-031103.json","markdown":"https://secwatch.observer/filing/0001493152-26-031103.md","text":"https://secwatch.observer/filing/0001493152-26-031103.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053369/000149315226031103/0001493152-26-031103-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053369/000149315226031103/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T20:53:21.081277+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}